Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Payables (2019 - 2026)

C4 Therapeutics has reported Payables over the past 8 years, most recently at $773000.0 for Q1 2026.

  • For Q1 2026, Payables rose 13.18% year-over-year to $773000.0; the TTM value through Mar 2026 reached $773000.0, up 13.18%, while the annual FY2025 figure was $858000.0, 35.39% down from the prior year.
  • Payables for Q1 2026 was $773000.0 at C4 Therapeutics, down from $858000.0 in the prior quarter.
  • Over five years, Payables peaked at $4.4 million in Q2 2022 and troughed at $683000.0 in Q1 2025.
  • A 5-year average of $1.7 million and a median of $1.3 million in 2025 define the central range for Payables.
  • Biggest five-year swings in Payables: crashed 73.99% in 2022 and later soared 142.72% in 2025.
  • Year by year, Payables stood at $1.2 million in 2022, then grew by 23.38% to $1.4 million in 2023, then fell by 8.16% to $1.3 million in 2024, then crashed by 35.39% to $858000.0 in 2025, then decreased by 9.91% to $773000.0 in 2026.
  • Business Quant data shows Payables for CCCC at $773000.0 in Q1 2026, $858000.0 in Q4 2025, and $1.3 million in Q3 2025.